A Randomized, Double-blind, Placebo Controlled Study to Assess the Safety and Tolerability of HAL-MRE1 Subcutaneous Immunotherapy in Adult Subjects With Ragweed Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2019
Price : $35 *
At a glance
- Drugs HAL MRE1 (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Adverse reactions; First in man
- Sponsors HAL Allergy
- 05 Aug 2019 Status changed from recruiting to completed.
- 11 Dec 2018 Status changed from not yet recruiting to recruiting.
- 07 Dec 2018 New trial record